Castle biosciences presents data at the asdp 56th annual meeting supporting decisiondx-melanoma test’s ability to identify t1 melanoma patients at low risk for a positive sentinel lymph node

Castle biosciences, inc. announced the presentation of data supporting the ability of the decisiondx®-melanoma gene expression profile (gep) test to identify t1 (tumor depth of 1 mm or less) melanoma patients at low risk for a positive sentinel lymph node (sln) at the american society of dermatopathology (asdp) 56th annual meeting in san diego from october 17-20. key findings: for patients with t1 tumors of any age and a class 1a test result, sln positivity was 3.5%, significantly less than patients with a class 1b-2b result (p=0.0005), and below the 5% threshold at which guidelines do not recommend the procedure. for patients with t1 tumors 55 years of age or older and a class 1a test result, sln positivity was 2.3%, significantly less than patients with a class 1b-2b result (p=0.002), and below the 5% threshold at which guidelines do not recommend the procedure. use of the decisiondx-melanoma test to guide slnb decisions in patients with t1 melanoma could reduce slnb surgical procedures by 80% in patients 55 years of age or older, as 272 of 339 patients who underwent this procedure had a class 1a result. class 1a patients with t1 melanoma had recurrence free survival of 96.9% and distant metastasis-free survival of 97.3% on a retrospective dataset of 345 t1 patients with long-term follow-up, supporting that this population can safely avoid the slnb surgical procedure.
CSTL Ratings Summary
CSTL Quant Ranking